Company intelligence / Profile preview

MatchBio

London, England, United Kingdommatchbiotx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

MatchBio is a University of Oxford spin-out developing next-generation CAR-T cell therapies with enhanced sensitivity to overcome antigen escape, aiming to reduce cancer relapse rates. The company was launched in January 2024 with £4.5M seed funding from Oxford Science Enterprises. No clinical data has been published as of May 2025, but the platform is positioned for preclinical validation.

Therapeutic areas: OncologyInfectious Diseases
Modalities: CAR-T cells (Chimeric Antigen Receptor T cells)Engineered immune cells
Industry: Biotech

Partnerships

University of Oxford Molecular Immunology Group / academic founders' labsFunded by Wellcome Trust, Medical Research Council, Guy Newton Translational Grant during foundational research phase before spinout formation

Beyond the preview

Go deeper on MatchBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MatchBio.

Explore the full profile